Clin2
NCT07784985Possibly a fitNot yet recruiting

Study of NST-628 for recurrent grade 4 brain tumor

Glioma, Recurrent High GradeGrade 4 Malignant Glioma

Part of Cancer clinical trials.

This study tests an experimental drug called NST-628 for people with a type of brain cancer (grade 4 glioma) that has returned or worsened after standard treatment. The drug is given before surgery, and you will have a biopsy or tumor removal to see how the drug works in your tumor.

Summary written for real people, not researchers, by Clin2.

Phase
Early Phase 1
Enrollment
12 people
Ages
18 years and older
Study type
Interventional

Who can take part

  • You must have a grade 4 brain tumor (glioma) that has progressed after standard treatments like surgery and radiation with chemotherapy.
  • You must have a tumor tissue sample that shows high levels of a protein called pERK.
  • You must be scheduled for surgery to remove the tumor, and the tumor must be visible on an MRI with contrast.
  • You must be 18 years or older and able to take oral medications.
  • You must not have significant heart problems, other serious medical conditions, or active infections like HIV, hepatitis B, or hepatitis C.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06773481Recruiting· Phase 1
BC008-1A injection for recurrent grade 4 glioma

This trial tests a new injection called BC008-1A for people with a grade 4 glioma (a type of brain cancer) that has come back after standard treatment. The goal is to see if the drug can help control the tumor and improve outcomes.

Beijing, Beijing Municipality
NCT06883747Recruiting· Early Phase 1
Study of BMS-986504 for recurrent brain tumor

This trial tests an experimental drug, BMS-986504, for people with recurrent glioblastoma (a type of brain cancer). The drug targets a specific genetic change in the tumor. It aims to see if the drug can help shrink or slow the tumor.

Phoenix, Arizona
NCT06482905Recruiting· Phase 1
CAR-T cell therapy for recurrent grade 4 brain tumors

This trial tests a new treatment called TX103 CAR-T cells for people with a grade 4 glioma (like glioblastoma) that has come back or gotten worse after standard treatment. The therapy uses your own immune cells that are specially trained to attack a marker called B7-H3 found on tumor cells.

Phoenix, Arizona
NCT07560865Recruiting· Phase 1
New Cell Therapy for Recurring Brain Cancer

This study tests FT536, a new cell-based treatment, for people with a specific type of brain cancer (WHO Grade 4 astrocytoma) that has come back after standard treatment. The trial combines the new therapy with surgery to see if it can help stop the cancer from growing further.

Minneapolis, Minnesota
NCT07392957Recruiting· Phase 1/Phase 2
Testing CTX-009 with CTX-471 for recurrent glioblastoma

This trial tests a combination of two experimental drugs, CTX-009 and CTX-471, for people whose glioblastoma has returned. The goal is to see if these drugs can help control the tumor.

St Louis, Missouri
NCT06804655Not yet recruiting· Phase 2
Personalized drug testing for stubborn brain tumors

This study tests a new way to choose treatment for people with brain tumors that have not responded to standard therapies. Your tumor sample is analyzed in the lab to find which drugs might work best for you, and then you receive a personalized treatment plan.

Basel, Basel-Landschaft

Hear when a new Glioma, Recurrent High Grade trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.